No abstract available
Keywords:
BCR-ABL1; chronic myeloid leukaemia; stem cells; therapy; trials.
Publication types
-
Clinical Trial, Phase II
-
Comparative Study
-
Letter
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Benzamides / administration & dosage*
-
Benzamides / adverse effects
-
Benzamides / therapeutic use
-
Cell Cycle / drug effects
-
Dasatinib
-
Drug Substitution
-
Drug Synergism
-
Follow-Up Studies
-
Fusion Proteins, bcr-abl / blood
-
Granulocyte Colony-Stimulating Factor / administration & dosage*
-
Granulocyte Colony-Stimulating Factor / adverse effects
-
Granulocyte Colony-Stimulating Factor / therapeutic use
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myeloid, Chronic-Phase / drug therapy*
-
Piperazines / administration & dosage*
-
Piperazines / adverse effects
-
Piperazines / therapeutic use
-
Protein Kinase Inhibitors / administration & dosage*
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use
-
Pulse Therapy, Drug
-
Pyrimidines / administration & dosage*
-
Pyrimidines / adverse effects
-
Pyrimidines / therapeutic use
-
Thiazoles / therapeutic use
-
Treatment Outcome
Substances
-
BCR-ABL1 fusion protein, human
-
Benzamides
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Thiazoles
-
Granulocyte Colony-Stimulating Factor
-
Imatinib Mesylate
-
Fusion Proteins, bcr-abl
-
nilotinib
-
Dasatinib